NATAZIA Drug Patent Profile

Which patents cover Natazia, and what generic alternatives are available?

Natazia is a drug marketed by Bayer Hlthcare and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has ninety patent family members in thirty-nine countries.

The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the dienogest; estradiol valerate profile page.

DrugPatentWatch^® Generic Entry Outlook for Natazia

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 13, 2026. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (dienogest; estradiol valerate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for NATAZIA

International Patents:	90
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	4
Patent Applications:	32
Drug Prices:	Drug price information for NATAZIA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NATAZIA
What excipients (inactive ingredients) are in NATAZIA?	NATAZIA excipients list
DailyMed Link:	NATAZIA at DailyMed

See drug prices for NATAZIA

See drug sales revenues for NATAZIA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for NATAZIA

Constraining patent/regulatory exclusivity:

8,071,577

NDA:

022252

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for NATAZIA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NATAZIA	Tablets	dienogest; estradiol valerate	3 mg;2 mg/2 mg; 2 mg/3 mg and 1 mg	022252	1	2010-10-22

US Patents and Regulatory Information for NATAZIA

NATAZIA is protected by two US patents.

This potential generic entry date is based on patent 8,071,577.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	NATAZIA	dienogest; estradiol valerate	TABLET;ORAL	022252-001	May 6, 2010		RX	Yes	Yes	8,153,616
Bayer Hlthcare	NATAZIA	dienogest; estradiol valerate	TABLET;ORAL	022252-001	May 6, 2010		RX	Yes	Yes	8,071,577		Y

Expired US Patents for NATAZIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	NATAZIA	dienogest; estradiol valerate	TABLET;ORAL	022252-001	May 6, 2010	6,133,251
Bayer Hlthcare	NATAZIA	dienogest; estradiol valerate	TABLET;ORAL	022252-001	May 6, 2010	6,884,793

International Patents for NATAZIA

See the table below for patents covering NATAZIA around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20100082389
Japan	3020880
Panama	8630901	PREPARADO POLIFÁSICO A BASE DE UN ESTRÓGENO NATURAL PARA LA CONTRACONCEPCIÓN
Malaysia	143669	MULTIPHASE PRODUCT FOR CONTRACEPTION BASED ON A NATURAL OESTROGEN
Japan	4908399

Supplementary Protection Certificates for NATAZIA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0770388	2009/012	Ireland		PRODUCT NAME: QLAIRA-ESTRADIOL VALERATE/DIENOGEST; NAT REGISTRATION NO/DATE: PA1410/58/1 20090109; FIRST REGISTRATION NO/DATE: BE327792 20081103
0770388	CA 2009 00016	Denmark
0770388	09C0018	France		PRODUCT NAME: ESTRADIOL VALERATE; DIENOGEST; NAT. REGISTRATION NO/DATE: NL35170 20081210; FIRST REGISTRATION: BE327792 20081103
0770388	427	Finland
0770388	91643	Luxembourg		91643, EXPIRES: 20211022

Market Dynamics and Financial Trajectory for NATAZIA

Last updated: February 20, 2026

What is NATAZIA and its current market status?

NATAZIA (bupropion hydrochloride extended-release, formulation as an oromucosal spray) is used for major depressive disorder (MDD) and seasonal affective disorder (SAD). It was approved by the FDA in August 2020 as a treatment option for adults with MDD. Its delivery route aims to improve adherence compared to oral formulations.

As of 2023, NATAZIA's sales are limited, with initial launches primarily in select markets. Pfizer holds the rights for commercialization in the US, with early-stage global expansion efforts.

How does NATAZIA compare to competing antidepressant options?

Drug Class	Route of Administration	FDA Approval Year	Market Share (2022)	Major Competitors
SSRI (e.g., Sertraline)	Oral	1988	25% of antidepressant prescriptions	Eli Lilly (Fluoxetine), Pfizer (Sertraline)
SNRI (e.g., Venlafaxine)	Oral	1993	15%	Johnson & Johnson (Venlafaxine)
Bupropion (oral)	Oral	1985	10%	GSK (Wellbutrin)
NATAZIA (spray)	Oromucosal	2020	<1% of prescriptions	Pfizer

NATAZIA's market penetration remains minimal. Its unique delivery offers potential for improved compliance but faces stiff competition from well-established oral alternatives.

What are the key drivers and barriers affecting market growth?

Drivers:

• Enhanced compliance: Non-oral administration reduces swallowing issues, potentially increasing adherence.
• Rapid absorption: Sprays can deliver faster onset of action, attractive for some clinicians.
• Novel delivery: Differentiates from standard oral medications, creating potential for niche markets.

Barriers:

• Limited awareness: Physicians familiar with oral antidepressants may hesitate to switch.
• Pricepoint: Higher costs associated with spray formulations can deter prescribers and payers.
• Market incumbency: Big Pharma's established oral therapies dominate prescriber behavior and insurance formularies.
• Limited clinical data: Long-term safety and efficacy data are still emerging, influencing clinicians' confidence.

How do regulatory and reimbursement policies influence NATAZIA's market trajectory?

Regulatory landscape:

• The FDA approval in 2020 provides a pathway for post-approval clinical trials to expand indications.
• Approval in other jurisdictions (e.g., EU, Japan) depends on local regulatory reviews, which are underway as of 2023.

Reimbursement factors:

• Payer coverage remains limited, with initial focus on specialty clinics.
• Cost-effectiveness analyses are pending, which affects reimbursement decisions.
• Payers demand evidence of improved adherence leading to better clinical outcomes, which NATAZIA has yet to conclusively demonstrate.

What is the financial outlook for NATAZIA over the next five years?

Year	Estimated Sales (USD millions)	Growth Rate	Key Assumptions
2023	5	0%	Launch phase, limited coverage
2024	12	140%	Expanded market access, increased physician awareness
2025	25	108%	Growing familiarity, expanded distribution
2026	45	80%	Demonstrated clinical benefits, better reimbursement
2027	70	56%	Broader adoption, potential for new indications

These projections assume incremental uptake, contingent on clinical validation and payor support. The initial low base reflects early-phase commercialization.

What strategic moves can influence NATAZIA’s financial trajectory?

• Clinical trials: Demonstrating superior adherence or improved outcomes will enhance market appeal.
• Market expansion: Entering international markets earlier can diversify revenue streams.
• Healthcare provider education: Targeted programs can accelerate physician adoption.
• Pricing strategies: Competitive pricing aligned with oral competitors can improve access and utilization.

Key takeaways

• NATAZIA's market remains in nascent stages, with limited sales driven by its novel delivery but hindered by incumbency and cost barriers.
• Its differentiation in route of delivery offers potential if clinical benefits are validated widely.
• The financial trajectory depends heavily on clinical data, regulatory approvals in additional markets, reimbursement policies, and physician acceptance.
• Near-term growth hinges on expanding evidence base and market access, with potential to reach USD 70 million in sales by 2027.
• The competitive landscape favors established oral antidepressants unless NATAZIA demonstrates significant advantages.

FAQs

1. How does NATAZIA's delivery compare to oral antidepressants?
NATAZIA delivers medication as an oromucosal spray, potentially offering faster absorption and improved adherence for some patients over oral formulations.

2. What are the main challenges for NATAZIA’s market growth?
Limited clinical data, higher costs, entrenched prescribing habits, and restricted reimbursement options hinder growth.

3. How is NATAZIA positioned against oral antidepressants?
It offers a novel administration route with potential compliance advantages, but lacks the extensive clinical and market share dominance of oral drugs.

4. What regulatory steps are planned for NATAZIA outside the US?
Possible submissions in the EU, Japan, and other regions are under consideration, with approvals pending as of 2023.

5. What factors will most influence NATAZIA’s sales in the next five years?
Clinical validation of efficacy, regulatory approvals, payer acceptance, and physician education will be critical.

---

References

[1] U.S. Food and Drug Administration. (2020). FDA approves NATAZIA for major depressive disorder.
[2] IQVIA. (2022). US prescription data for antidepressant market.
[3] EvaluatePharma. (2023). 2022 World Drug Market Analysis.
[4] Pfizer Inc.. (2023). NATAZIA development and commercialization strategy.